ImmuNext is a biopharma company, developing antibody-based therapeutics and novel recombinant fusion proteins to modulate the immune system to treat cancer and autoimmune diseases.
The ImmuNext technology is based on discoveries made in Dr. Noelles labs at the Geisel School of Medicine at Dartmouth and Kings College, London.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/immunext” connections=”true” suffix=””]
In Jan 2017, ImmuNext granted Sanofi an exclusive, worldwide license to develop and commercialize INX-021, a CD40L monoclonal antibody in preclinical development that is overactive in many autoimmune diseases including Lupus and Multiple Sclerosis, with potential milestone payments to ImmuNext under the agreement could total $500 Mn.
In Dec 2016, ImmuNext granted Roche a worldwide, exclusive license to develop and commercialize therapeutics that agonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway, with potential milestone payments to ImmuNext under the agreement could total $400 Mn alongwith up to double digits royalties on sales of products.
In Sep. 2012, ImmuNext grant Janssen Biotech Inc., a worldwide, exclusive clinical development and commercialization rights to the therapeutics that antagonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway. ImmuNext under the agreement got upfront and milestone payments, worth more than $150 Mn USD.
Since Incorporation, ImmuNext has recieved more than $10 Mn in form of various SBIR awards from the National Institutes of Health.
Recover your password.
A password will be e-mailed to you.